Igor Vivanco

13.0k total citations · 1 hit paper
28 papers, 7.0k citations indexed

About

Igor Vivanco is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Igor Vivanco has authored 28 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Igor Vivanco's work include PI3K/AKT/mTOR signaling in cancer (10 papers), Lung Cancer Treatments and Mutations (5 papers) and Prostate Cancer Treatment and Research (4 papers). Igor Vivanco is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (10 papers), Lung Cancer Treatments and Mutations (5 papers) and Prostate Cancer Treatment and Research (4 papers). Igor Vivanco collaborates with scholars based in United States, United Kingdom and Switzerland. Igor Vivanco's co-authors include Charles L. Sawyers, Ingo K. Mellinghoff, Chris Tran, James Kuo, Douglas C. Saffran, Daniel Afar, René Hubert, Arthur Raitano, Aya Jakobovits and Emily Chen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Igor Vivanco

28 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

2002 4.9k citations Igor Vivanco, Charles L. Sawyers Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Igor Vivanco United States	20	5.0k	2.0k	1.3k	1.3k	778	28	7.0k
Hui‐Wen Lo United States	48	4.5k 0.9×	3.3k 1.7×	1.5k 1.1×	1.5k 1.2×	664 0.9×	113	7.7k
Qing‐Bai She United States	33	5.0k 1.0×	1.8k 0.9×	842 0.6×	999 0.8×	786 1.0×	73	6.6k
Richard B. Lock Australia	53	5.1k 1.0×	2.8k 1.5×	952 0.7×	1.2k 0.9×	659 0.8×	260	8.7k
Deborah A. Altomare United States	37	4.0k 0.8×	1.7k 0.9×	1.3k 0.9×	1.0k 0.8×	826 1.1×	69	6.4k
Antonella De Luca Italy	38	3.6k 0.7×	3.4k 1.8×	1.7k 1.3×	1.4k 1.1×	619 0.8×	102	6.8k
Sug Hyung Lee South Korea	52	6.4k 1.3×	2.6k 1.3×	1.4k 1.0×	2.2k 1.7×	1.1k 1.4×	267	9.2k
Ron Bose United States	33	3.5k 0.7×	3.1k 1.6×	1.3k 0.9×	1.2k 1.0×	596 0.8×	94	6.7k
Alex N. Bullock United Kingdom	49	6.1k 1.2×	2.8k 1.4×	756 0.6×	1.1k 0.8×	802 1.0×	108	8.7k
Paul T. Kirschmeier United States	39	5.0k 1.0×	3.2k 1.6×	1.2k 0.9×	1.4k 1.1×	469 0.6×	99	7.5k
Ben Ho Park United States	43	5.2k 1.0×	2.5k 1.3×	1.5k 1.1×	2.2k 1.7×	660 0.8×	142	8.0k

Countries citing papers authored by Igor Vivanco

Since Specialization

Citations

This map shows the geographic impact of Igor Vivanco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor Vivanco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor Vivanco more than expected).

Fields of papers citing papers by Igor Vivanco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor Vivanco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor Vivanco. The network helps show where Igor Vivanco may publish in the future.

Co-authorship network of co-authors of Igor Vivanco

This figure shows the co-authorship network connecting the top 25 collaborators of Igor Vivanco. A scholar is included among the top collaborators of Igor Vivanco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Igor Vivanco. Igor Vivanco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gutiérrez, Nuria Martí, Luise Wolf, Stefka Tyanova, et al.. (2022). DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF. Life Science Alliance. 5(9). e202101235–e202101235. 8 indexed citations

Coleman, Niamh, et al.. (2021). Targeting un-MET needs in advanced non-small cell lung cancer. Lung Cancer. 164. 56–68. 13 indexed citations

Coleman, Niamh, et al.. (2021). Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine. Pharmacogenomics and Personalized Medicine. Volume 14. 1517–1535. 41 indexed citations

Tzankov, Alexandar, Ruth Plummer, Igor Vivanco, et al.. (2020). 382P The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM). Annals of Oncology. 31. S404–S404. 2 indexed citations

Kostaras, Eleftherios, Teresa Kaserer, Pedro Casado, et al.. (2020). A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity. British Journal of Cancer. 123(4). 542–555. 29 indexed citations

Stein, Shayna, Rui Zhao, Hiroshi Haeno, Igor Vivanco, & Franziska Michor. (2018). Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Computational Biology. 14(1). e1005924–e1005924. 31 indexed citations

Oldrini, Barbara, Wan-Ying Hsieh, Hediye Erdjument‐Bromage, et al.. (2017). EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. Nature Communications. 8(1). 2035–2035. 24 indexed citations

Tanos, B, Susana Salvarezza, Igor Vivanco, et al.. (2015). IQGAP1 Controls Tight Junction Formation Through Differential Regulation of Claudin Recruitment. Journal of Cell Science. 128(5). 853–62. 19 indexed citations

Vivanco, Igor. (2014). Targeting molecular addictions in cancer. British Journal of Cancer. 111(11). 2033–2038. 32 indexed citations

10.

Vivanco, Igor & Ingo K. Mellinghoff. (2010). Epidermal growth factor receptor inhibitors in oncology. Current Opinion in Oncology. 22(6). 573–578. 43 indexed citations

11.

Regales, Lucía, Yixuan Gong, Ronglai Shen, et al.. (2009). Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Journal of Clinical Investigation. 119(10). 3000–10. 297 indexed citations

12.

Li, Peng, Ting-Ting Wu, Jason Tchieu, et al.. (2009). Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. Journal of General Virology. 91(2). 463–469. 37 indexed citations

13.

Meng, Shasha, Selvaraju Veeriah, Ingo K. Mellinghoff, et al.. (2009). 14-3-3σ and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell Cycle. 8(14). 2238–2246. 7 indexed citations

14.

Jiao, Jing, Shunyou Wang, Rong Qiao, et al.. (2007). Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development. Cancer Research. 67(13). 6083–6091. 128 indexed citations

15.

Vivanco, Igor, Nicolaos Palaskas, Chris Tran, et al.. (2007). Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. Cancer Cell. 11(6). 555–569. 199 indexed citations

16.

Lu, Kan, Shaojun Zhu, Ederlyn Q. Dia, et al.. (2006). Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells. Cancer Research. 66(16). 7864–7869. 179 indexed citations

17.

Mellinghoff, Ingo K., Igor Vivanco, Andrew Kwon, et al.. (2004). HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 6(5). 517–527. 262 indexed citations

18.

Vivanco, Igor & Charles L. Sawyers. (2002). The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nature reviews. Cancer. 2(7). 489–501. 4890 indexed citations breakdown →

19.

Jain, Anjali, Amanda Lam, Igor Vivanco, Michael Carey, & Robert E. Reiter. (2002). Identification of an Androgen-Dependent Enhancer within the Prostate Stem Cell Antigen Gene. Molecular Endocrinology. 16(10). 2323–2337. 47 indexed citations

20.

Afar, Daniel, Igor Vivanco, René Hubert, et al.. (2001). Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.. PubMed. 61(4). 1686–92. 199 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact